DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from Amyotrophic Lateral Sclerosis Pipeline Insight Report

• Amyotrophic Lateral Sclerosis Pipeline report offers a rich analysis of 100+ key players and 100+ key therapies.
• Amyotrophic Lateral Sclerosis pipeline comprises therapies in different stages of the clinical phase such as BIIB067, ANX005, AMX0035, MN-166, BLZ945, AP-101, AS-202, Arimoclomol, ALZT-OP1a, AT1501, HK001, Q-Cells, and several others expected to get launched in the next decade.
• Some of the key companies engaged in expanding the Amyotrophic Lateral Sclerosis Pipeline are Biogen, Annexon Biosciences, Amylyx Pharmaceuticals, MediciNova, Novartis, AL-S Pharma, Acurastem, Orphazyme, AZTherapies, ALS TDI, Everfront Biotech, Q Therapeutics, among others.
• The companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic Lateral Sclerosis (ALS) R&D. The therapies under development are focused on novel approaches to treat/improve Amyotrophic Lateral Sclerosis (ALS).

 

Request for Sample to know more about the therapies that are set to add maximum revenue @ Amyotrophic Lateral Sclerosis Emerging Therapies and Forecast

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis is a rare neurological disease that primarily affects the nerve cells (neurons) responsible for controlling voluntary muscle movement (those muscles we choose to move). Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. ALS belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. As motor neurons degenerate, they stop sending messages to the muscles and the muscles gradually weaken, start to twitch, and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. Early symptoms of ALS usually include muscle weakness or stiffness. Gradually all voluntary muscles are affected, and individuals lose their strength and the ability to speak, eat, move, and even breathe. Most people with ALS die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years.

 

Recent Breakthroughs in the Amyotrophic Lateral Sclerosis Treatment Landscape

• In May 2021, Seelos Therapeutics announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
• In May 2021, Aeterna Zentaris announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease).
• In May 2021, Orphazyme announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety signals were reported in the trial.
• In March 2021, Retrotope announced that the first patient has been dosed in a multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).

 

For more information on emerging drugs, visit Amyotrophic Lateral Sclerosis Pipeline Analysis

 

Amyotrophic Lateral Sclerosis Emerging Drugs

• AMX0035: Amylyx Pharmaceuticals
• BIIB067: Biogen
• Masitinib: AB Sciences
• Ravulizumab: Alexion Pharmaceuticals
• Autologous MSC-NTF cells: BrainStorm Cell Therapeutics

 

DelveInsight’s Amyotrophic Lateral Sclerosis Pipeline report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Request for Sample to know more @ Amyotrophic Lateral Sclerosis Pipeline Analysis, Companies and Futuristic Trends

 

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report

• Coverage: Global
• Key Players: Biogen, Annexon Biosciences, Amylyx Pharmaceuticals, MediciNova, Novartis, AL-S Pharma, Acurastem, Orphazyme, AZTherapies, ALS TDI, Everfront Biotech, Q Therapeutics, Biohaven Pharmaceuticals, Neuropore Therapies, Retrotope, Seelos Therapeutics, among others.
• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: BIIB067, ANX005, AMX0035, MN-166, BLZ945, AP-101, AS-202, Arimoclomol, ALZT-OP1a, AT1501, HK001, Q-Cells, Verdiperstat, NPT 520-34, RT001, SLS-005, among others.

 

Table of content

1. Introduction
2. Executive Summary
3. Amyotrophic Lateral Sclerosis (ALS): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Preregistration)
7. AMX0035: Amylyx Pharmaceuticals
8. Mid Stage Products (Phase II)
9. ANX005: Annexon
10. Early stage products (Phase I/II)
11. Q-cells: Q therapeutics
12. Inactive Products
13. Amyotrophic Lateral Sclerosis (ALS) Key Companies
14. Amyotrophic Lateral Sclerosis (ALS) Key Products
15. Amyotrophic Lateral Sclerosis (ALS)- Unmet Needs
16. Amyotrophic Lateral Sclerosis (ALS)- Market Drivers and Barriers
17. Amyotrophic Lateral Sclerosis (ALS)- Future Perspectives and Conclusion
18. Amyotrophic Lateral Sclerosis (ALS) Analyst Views
19. Amyotrophic Lateral Sclerosis (ALS) Key Companies
20. Appendix

 

Dive deep into rich insights for drugs for Amyotrophic Lateral Sclerosis treatment, visit @ New Drug for Amyotrophic Lateral Sclerosis Treatment

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/